These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 25333986)

  • 1. Inconsistencies among European Union pharmaceutical regulator safety communications: a cross-country comparison.
    Zeitoun JD; Lefèvre JH; Downing N; Bergeron H; Ross JS
    PLoS One; 2014; 9(10):e109100. PubMed ID: 25333986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulatory anticipation of postmarket safety problems for novel medicines approved by the EMA between 2001 and 2010: a cross-sectional study.
    Zeitoun JD; Lefèvre JH; Downing NS; Bergeron H; Ross JS
    Pharmacoepidemiol Drug Saf; 2016 Jun; 25(6):687-94. PubMed ID: 26554874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A decade of safety-related regulatory action in the Netherlands: a retrospective analysis of direct healthcare professional communications from 1999 to 2009.
    Mol PG; Straus SM; Piening S; de Vries JT; de Graeff PA; Haaijer-Ruskamp FM
    Drug Saf; 2010 Jun; 33(6):463-74. PubMed ID: 20486729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prescribing of rosiglitazone and pioglitazone following safety signals: analysis of trends in dispensing patterns in the Netherlands from 1998 to 2008.
    Ruiter R; Visser LE; van Herk-Sukel MP; Geelhoed-Duijvestijn PH; de Bie S; Straus SM; Mol PG; Romio SA; Herings RM; Stricker BH
    Drug Saf; 2012 Jun; 35(6):471-80. PubMed ID: 22540371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of safety issues with HIV drugs on the approval process of other drugs in the same class: an analysis of European Public Assessment Reports.
    Arnardottir AH; Haaijer-Ruskamp FM; Straus SM; de Graeff PA; Mol PG
    Drug Saf; 2011 Nov; 34(11):1101-14. PubMed ID: 21981437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preparation of Direct Healthcare Professional Communication: An Exploratory Study on the Experiences and Perceptions of European Pharmaceutical Companies and the EMA.
    Boskovic A; Møllebæk M; Kaae S
    Ther Innov Regul Sci; 2020 May; 54(3):631-639. PubMed ID: 33301149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulatory review time and post-market safety events for novel medicines approved by the EMA between 2001 and 2010: a cross-sectional study.
    Zeitoun JD; Lefèvre JH; Downing NS; Bergeron H; Ross JS
    Br J Clin Pharmacol; 2015 Oct; 80(4):716-26. PubMed ID: 25808713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparation of Direct Healthcare Professional Communication: An Exploratory Study on the Experiences and Perceptions of European Pharmaceutical Companies and the EMA.
    Boskovic A; Møllebæk M; Kaae S
    Ther Innov Regul Sci; 2019 Sep; ():2168479019871041. PubMed ID: 31510799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are monitoring instructions provided in direct healthcare professional communications (DHPCs) of sufficient quality? A retrospective analysis of DHPCs sent out between 2007 and 2018.
    Højer MG; De Bruin ML; Boskovic A; Hallgreen CE
    BMJ Open; 2020 May; 10(5):e036498. PubMed ID: 32398337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety Communication Tools and Healthcare Professionals' Awareness of Specific Drug Safety Issues in Europe: A Survey Study.
    de Vries ST; van der Sar MJM; Coleman AM; Escudero Y; Rodríguez Pascual A; Maciá Martínez MÁ; Cupelli A; Baldelli I; Šipić I; Andrić A; Michan L; Denig P; Mol PGM;
    Drug Saf; 2018 Jul; 41(7):713-724. PubMed ID: 29500798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety-related regulatory actions for biologicals approved in the United States and the European Union.
    Giezen TJ; Mantel-Teeuwisse AK; Straus SM; Schellekens H; Leufkens HG; Egberts AC
    JAMA; 2008 Oct; 300(16):1887-96. PubMed ID: 18940975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secret safety warnings on medicines: A case study of information access requests.
    Torka M; Mintzes B; Bhasale A; Fabbri A; Perry L; Lexchin J
    Pharmacoepidemiol Drug Saf; 2019 Apr; 28(4):551-555. PubMed ID: 30840349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Communication on Safety of Medicines in Europe: Current Practices and General Practitioners' Awareness and Preferences.
    de Vries ST; van der Sar MJM; Cupelli A; Baldelli I; Coleman AM; Montero D; Šipić I; Andrić A; Wennberg A; Ahlqvist-Rastad J; Denig P; Mol PGM;
    Drug Saf; 2017 Aug; 40(8):729-742. PubMed ID: 28540672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dissemination of Direct Healthcare Professional Communications on Medication Errors for Medicinal Products in the EU: An Explorative Study on Relevant Factors.
    Hoeve CE; de Vries E; Mol PGM; Sturkenboom MCJM; Straus SMJM
    Drug Saf; 2021 Jan; 44(1):73-82. PubMed ID: 33355904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fighting trafficking of falsified and substandard medicinal products in Russia.
    Fayzrakhmanov NF
    Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An investigation into drug products withdrawn from the EU market between 2002 and 2011 for safety reasons and the evidence used to support the decision-making.
    McNaughton R; Huet G; Shakir S
    BMJ Open; 2014 Jan; 4(1):e004221. PubMed ID: 24435895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Granting marketing authorisation for medicines in South East European countries: the point of view of the authority.
    Tomić S; Sucić AF; Martinac AI
    Regul Toxicol Pharmacol; 2010; 57(2-3):325-32. PubMed ID: 20385190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of direct healthcare professional communication on prescribing practice in the UK hospital setting: an interrupted time series analysis.
    Thomas SK; Hodson J; McIlroy G; Dhami A; Coleman JJ
    Drug Saf; 2013 Jul; 36(7):557-64. PubMed ID: 23657825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. When direct health-care professional communications have an impact on inappropriate and unsafe use of medicines.
    Reber KC; Piening S; Wieringa JE; Straus SM; Raine JM; de Graeff PA; Haaijer-Ruskamp FM; Mol PG
    Clin Pharmacol Ther; 2013 Apr; 93(4):360-5. PubMed ID: 23443752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.